Cargando…

NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages

BACKGROUND: To operationalize the National Institute on Aging – Alzheimer's Association (NIA‐AA) Research Framework for Alzheimer's Disease 6‐stage continuum of clinical progression for persons with abnormal amyloid. METHODS: The Mayo Clinic Study of Aging is a population‐based longitudina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Ronald C., Wiste, Heather J., Weigand, Stephen D., Fields, Julie A., Geda, Yonas E., Graff‐Radford, Jonathan, Knopman, David S., Kremers, Walter K., Lowe, Val, Machulda, Mary M., Mielke, Michelle M., Stricker, Nikki H., Therneau, Terry M., Vemuri, Prashanthi, Jack, Clifford R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131266/ https://www.ncbi.nlm.nih.gov/pubmed/33772866 http://dx.doi.org/10.1002/ana.26071

Ejemplares similares

Longitudinal tau PET in ageing and Alzheimer’s disease
por: Jack, Clifford R, et al.
Publicado: (2018)

Association of Cerebrovascular Imaging Biomarkers, Depression, and Anxiety, with Mild Cognitive Impairment
por: Vassilaki, Maria, et al.
Publicado: (2023)

Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study
por: Jack, Clifford R., et al.
Publicado: (2017)

Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework
por: Jack, Clifford R., et al.
Publicado: (2019)

Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk
por: Jack, Clifford R., et al.
Publicado: (2022)

Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study
por: Jack, Clifford R., et al.
Publicado: (2015)

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
por: Jack, Clifford R, et al.
Publicado: (2019)

Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults
por: Arenaza-Urquijo, Eider M., et al.
Publicado: (2020)

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings
por: Jack, Clifford R., et al.
Publicado: (2015)

Brain amyloid, cortical thickness, and changes in activities of daily living
por: Vassilaki, Maria, et al.
Publicado: (2020)

Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging
por: Vemuri, Prashanthi, et al.
Publicado: (2019)

Associations of quantitative susceptibility mapping with Alzheimer’s disease clinical and imaging markers
por: Cogswell, Petrice M., et al.
Publicado: (2020)

Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
por: Therneau, Terry M., et al.
Publicado: (2021)

Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population
por: Poulakis, Konstantinos, et al.
Publicado: (2021)

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes
por: Marks, Jordan D., et al.
Publicado: (2021)

Predicting future rates of tau accumulation on PET
por: Jack, Clifford R, et al.
Publicado: (2020)

Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults
por: Ramanan, Vijay K, et al.
Publicado: (2019)

White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline
por: Vemuri, Prashanthi, et al.
Publicado: (2021)

Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
por: Krell-Roesch, Janina, et al.
Publicado: (2019)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study
por: Vemuri, Prashanthi, et al.
Publicado: (2016)

Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
por: Jack, Clifford R., et al.
Publicado: (2014)

Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology
por: Ramanan, Vijay K., et al.
Publicado: (2021)

Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology
por: Shir, Dror, et al.
Publicado: (2022)

Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging
por: Neth, Bryan J., et al.
Publicado: (2020)

Evidence against a temporal association between cerebrovascular disease and Alzheimer’s disease imaging biomarkers
por: Cogswell, Petrice M., et al.
Publicado: (2023)

White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging
por: Machulda, Mary M., et al.
Publicado: (2021)

Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline
por: Pink, Anna, et al.
Publicado: (2023)

Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition
por: Raghavan, Sheelakumari, et al.
Publicado: (2021)

A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment
por: Pink, Anna, et al.
Publicado: (2021)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

Quantity and quality of mental activities and the risk of incident mild cognitive impairment
por: Krell-Roesch, Janina, et al.
Publicado: (2019)

Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging
por: Vemuri, Prashanthi, et al.
Publicado: (2018)

Effects of de-facing software mri_reface on utility of imaging biomarkers used in Alzheimer’s disease research
por: Schwarz, Christopher G., et al.
Publicado: (2023)

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2018)

Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values
por: Schwarz, Christopher G., et al.
Publicado: (2018)

Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging
por: Krell‐Roesch, Janina, et al.
Publicado: (2021)

Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition
por: Vemuri, Prashanthi, et al.
Publicado: (2016)

FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging
por: Krell-Roesch, Janina, et al.
Publicado: (2016)

Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging
por: Machulda, Mary M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_atu5ld05casr2pub138m7oj31g